

Learn more about the role of the epithelium in different phenotypes of chronic rhinosinusitis



AERD, aspirin-exacerbated respiratory disease; AFRS, allergic fungal rhinosinusitis

Aspirin-exacerbated respiratory disease (AERD) (1/3)

Epicentral UNDERSTANDING THE CENTRAL ROLE OF THE EPITHELIOM IN SEVERE ASTHINA AND BEVOND

or NSAID-exacerbated respiratory disease (N-ERD)

What is AERD?

- AERD is characterized by:^{1,2}
 - Chronic eosinophilic rhinosinusitis
 - Nasal polyposis
 - Asthma
 - Acute respiratory reactions to NSAIDs with COX-1 inhibitory activity
- NSAID ingestion triggers:^{2,3}
 - Upper and lower airway symptoms (eg rhinorrhea, coughing, and bronchospasm)
 - Non-respiratory symptoms

 (eg pruritus, abdominal pain, and vomiting)

Prevalence

 In a meta-analysis of 27 studies from 13 countries, including the USA, AERD was estimated to be present in about:^{4*}



14.9% of patients with **severe asthma**





 However, these could be underestimates; a US study of electronic health records identified that 12.4% of individuals exhibiting characteristics of clinical AERD were undiagnosed^{5†}

Diagnosis

- Diagnosis is mainly based on patient history of at least one reaction to NSAIDs^{1,6}
- If history is unclear, provocation challenge with NSAIDs can confirm diagnosis^{1,6}
- A high proportion of patients with AERD also **experience alcohol-induced respiratory reactions**, awareness of which might prompt clinical investigation^{7,8}

*Prevalence rates obtained from a meta-analysis of clinical trials in adult patients with AERD published on or before June 16, 2013; [†]Suspected cases of AERD identified using an informatics algorithm to search electronic health records of patients (age ≥18 years) from 2004–2014. Confirmation of diagnosis and classification as diagnosed or undiagnosed were performed by two clinical experts independently
 AERD, aspirin-exacerbated respiratory disease; COX-1, cyclooxygenase-1; CRS, chronic rhinosinusitis; N-ERD, NSAID-exacerbated respiratory disease; NSAID, non-steroidal anti-inflammatory drug
 Dominas C, et al. Laryngoscope Investig Otolaryngol 2020;5:360–367; 2. Laidlaw TM. World J Otorhinolaryngol Head Neck Surg 2018;4:162–168; 3. Badrani JH, Doherty TA. Curr Opin Allergy Clin Immunol 2021;21:65–70;
 Rajan JP, et al. J Allergy Clin Immunol 2015;135:676–681.e1; 5. Cahill KN, et al. J Allergy Clin Immunol 2017;139:819–825.e6; 6. Fokkens WJ, et al. Rhinology 2020;58(Suppl S29):1–464;
 Cardet JC, et al. J Allergy Clin Immunol Pract 2014;2:208–213; 8. Ramos CL, et al. Ann Allergy Asthma Immunol 2023;131:382–384

Aspirin-exacerbated respiratory disease (AERD) (2/3)





Burden of disease Quality of life Disease severity • A US study showed that, compared with patients with CRSwNP alone or CRSwNP and comorbid asthma, patients with AERD:¹ physical and mental health⁴ **Risks of aspirin desensitization** Had more severe sinus disease Were more likely to have Underwent more (based on sinus mucosal thickening **OCS-dependent disease** sinus surgeries • There is evidence that aspirin desensitization observed on CT scans) benefits patients with AERD by alleviating

Burden of revision surgery

• Similarly, a UK audit identified that the prevalence of AERD was significantly higher in patients with CRS who had **undergone multiple sinonasal surgeries** compared with those who had not²

- Data suggest that patients with AERD, compared with CRSwNP alone or CRSsNP, suffer the **most** burdensome symptoms,³ and nasal congestion, anosmia, and hyposmia in particular impact their
- symptoms and improving lung function following 6 months of treatment⁵
- However, the treatment is also associated with an increased risk of adverse events including gastritis and gastrointestinal bleeding⁵

AERD, aspirin-exacerbated respiratory disease; CRS, chronic rhinosinusitis; CRSsNP, CRS without nasal polyps; CRSwNP, CRS with nasal polyps; CT, computed tomography; N-ERD, NSAID-exacerbated respiratory disease; NSAID, non-steroidal anti-inflammatory drug; OCS, oral corticosteroid

1. Stevens WW, et al. J Allergy Clin Immunol Pract 2017;5:1061–1070.e3; 2. Philpott C, et al. BMJ Open 2015;5:e006680; 3. Schneider S, et al. J Clin Med 2020;9:925;

4. Tchekmedyian R, et al. Clin Exp Allergy 2022;52:1414–1421; 5. Eraso I, et al. PLoS One 2021;16:e0247871




Aspirin-exacerbated respiratory disease (AERD) (3/3)



or NSAID-exacerbated respiratory disease (N-ERD)

Pathology and the role of epithelial cytokines

- AERD consists of chronic baseline inflammation (presenting as asthma and nasal polyposis) and acute hypersensitivity to COX-1 inhibitors¹
- Both phases are associated with overproduction of **pro-inflammatory CysLTs** and **PGD2**, and underproduction **of anti-inflammatory PGE2**^{1–3}
 - The underproduction of PGE2 has been linked to chronic underexpression or reduced function of COX-2 and/or PGES⁴
 - Ingested aspirin inhibits COX-1, thus compounding low levels of PGE2 and accounting for aspirin-induced reactions⁴
- Epithelial-derived **TSLP**, **IL-33**, and **IL-25** are thought to contribute to AERD pathogenesis by driving a **Type 2 immune response**:^{3,5,6}
 - TSLP and IL-33 stimulate mast cells to produce PGD2, which in turn recruits eosinophils, basophils, and ILC2s into the respiratory tissues^{5,6}
 - ILC2s release Type 2 cytokines IL-4, IL-5, and IL-13 which, in conjunction with CysLTs and PGD2, promote bronchoconstriction, eosinophilic tissue inflammation, and mucus production³
 - Additionally, PGD2 is thought to cause acute swelling of the sinuses and airways, leading to nasal congestion¹



The information presented in these figures has been simplified for illustration purposes. Mechanisms underlying AERD require further elucidation, and the illustrated pathway is a hypothesis only 5-LO, 5-lipoxygenase; AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; IgE, immunoglobulin E; IL, interleukin; ILC2, Type 2 innate lymphoid cell; LTA4, leukotriene A4; LTC4S, leukotriene C4 synthase; N-ERD, NSAID-exacerbated respiratory disease; NSAID, non-steroidal anti-inflammatory drug; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGE5, prostaglandin E synthase; PGH2, prostaglandin H2; Th, T helper; TSLP, thymic stromal lymphopoietin 1. Laidlaw TM. World J Otorhinolaryngol Head Neck Surg 2018;4:162–168; 2. Dominas C, et al. Laryngoscope Investig Otolaryngol 2020;5:360–367; 3. Badrani JH, Doherty TA. Curr Opin Allergy Clin Immunol 2021;21:65–70; 4. Laidlaw TM, Boyce JA. J Allergy Clin Immunol 2023;151:301–309; 5. Buchheit KM, et al. J Allergy Clin Immunol 2016;137:1566–1576.e5; 6. Sehanobish E, et al. Curr Opin Allergy Clin Immunol 2022;22:42–48




Allergic fungal rhinosinusitis (AFRS) (1/2)



What is AFRS?

- AFRS is a subtype of CRSwNP characterized by intense Type 2 inflammation in response to fungal colonization in the sinuses¹
- Major diagnostic criteria include:^{1,2}
 - Eosinophilic mucin
 - Absence of fungal invasion in sinus tissue
 - IgE-mediated hypersensitivity to fungi
 - Characteristic CT imaging
 - Fungi on staining
- MRI also aids diagnosis: typically scans show central hypointensity on T1- and T2-weighted images, and signal void on T2-weighted images¹





CT (A) and MRI (B) scans of a patient with AFRS with bilateral involvement

Prevalence and risk factors

- In the European Position Paper on Rhinosinusitis and Nasal Polyps 2020, AFRS was reported to account for about 5–10% of CRS cases²
- Patients are typically atopic and immunocompetent young adults¹
- Prevalence is higher in **warm** and **humid climates**, eg India and southern United States of America^{1,3}

Symptoms and burden

- Patients with AFRS present with symptoms of CRS that are refractory to conventional medical therapy and, notably, thick tenacious nasal discharge^{1,3}
- Patients with AFRS experience a high rate of revision surgeries, with a median interval of 2 years⁴
- Patients typically show highly elevated serum total and fungal-specific IgE levels compared with other CRSwNP subtypes³
- If untreated, complications such as visual disturbances, facial deformity, and bone erosion can occur¹

CT and MRI scans from Meng Y, et al. J Thorac Dis 2019;11:3569-3577

AFRS, allergic fungal rhinosinusitis; CRS, chronic rhinosinusitis; CRSwNP, CRS with nasal polyps; CT, computed tomography; IgE, immunoglobulin E; MRI, magnetic resonance imaging 1. Dykewicz MS, et al. J Allergy Clin Immunol 2018;142:341–351; 2. Fokkens WJ, et al. Rhinology 2020;58(Suppl S29):1–464; 3. Luong AU, et al. J Allergy Clin Immunol Pract 2022;10:3156–3162; 4. Philpott C, et al. BMJ Open 2015;5:e006680



Allergic fungal rhinosinusitis (AFRS) (2/2)



Pathology and the role of epithelial cytokines

- Fungal exposure can stimulate release of epithelial cytokines TSLP, IL-25, and IL-33, which drive downstream Type 2 immune responses:^{1,2}
 - Th2 cells and ILC2s produce IL-5, which promotes eosinophilia;
 Th2 cells produce IL-4 and IL-13, which induce B cells to produce IgE, including anti-fungal IgE¹⁻³
- In-vitro evidence suggests that epithelial permeability is increased in patients with AFRS owing to decreased expression of tight junction-associated proteins⁴




Figure adapted from Dykewicz MS, et al. J Allergy Clin Immunol 2018;142:341–351 and Luong AU, et al. J Allergy Clin Immunol Pract 2022;10:3156–3162 AFRS, allergic fungal rhinosinusitis; IgE, immunoglobulin E; IL, interleukin; ILC2, Type 2 innate lymphoid cell; Th, T helper; TSLP, thymic stromal lymphopoietin 1. Dykewicz MS, et al. J Allergy Clin Immunol 2018;142:341–351; 2. Shin S-H, et al. Int J Mol Sci 2023;24:2366; 3. Luong AU, et al. J Allergy Clin Immunol Pract 2022;10:3156–3162; 4.Den Beste KA, et al. Int Forum Allergy Rhinol 2013;3:19–25

